Autoinflammatory & rare systemic diseases
Inactivated SARS-CoV-2 vaccine does not increase the risk of relapse in patients with clinically inactive adult-onset Still’s disease
Authors' conclusion
Increased disease activity or relapse following vaccination with inactivated SARS-CoV-2 was rare in patients with inactive AOSD. Local and systemic adverse reactions were found to be mild and self-limiting.
Study context
- Population
- Clinically inactive adult-onset Still's disease (AOSD) patients visiting outpatient clinics
- Participants
- 122 patients
- Exposure
- Inactivated SARS-CoV-2 vaccine vs no vaccination
- Vaccinatedn = 60
- Outcome
- Relapse rate
Methodological detailspropensity-score matched
- Propensity-score matched
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
- No relapse occurred within 1 month after vaccination
Safety
No obvious adverse reactions (vaccinated participants)
- No obvious adverse reactions reported
- 75.0%
Severe reactions (vaccinated participants)
- None of the patients reported severe reactions
- 0
- Local and systemic adverse reactions mild and self-limiting
Original publication
Inactivated SARS-CoV-2 vaccine does not increase the risk of relapse in patients with clinically inactive adult-onset Still’s disease. Rheumatology (Oxford). Published 25 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →